Seiji Niho

7.5k citations

213 papers · 5.1k indexed · 2 hit papers · h-index 37

Impact in

Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in ⓘ

Oncology 149
- Lung Cancer Research Studies 87
- Colorectal Cancer Treatments and Studies 31
- Cancer Immunotherapy and Biomarkers 15
Pulmonary and Respiratory Medicine 144
- Lung Cancer Treatments and Mutations 116
- Lung Cancer Diagnosis and Treatment 62
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 17

Co-authors: Kōichi Goto (113 shared papers)Kiyotaka Yoh (112 shared papers)Hironobu Ohmatsu (89 shared papers)Yutaka Nishiwaki (49 shared papers)Shingo Matsumoto (62 shared papers)Kaoru Kubota (44 shared papers)Shigeki Umemura (55 shared papers)Yuichiro Ohe (65 shared papers)
Journals: Journal of Clinical Oncology (47 papers)Lung Cancer (25 papers)Annals of Oncology (20 papers)Journal of Thoracic Oncology (17 papers)Japanese Journal of Clinical Oncology (13 papers)
Partner nations: Japan United States South Korea

In The Last Decade

Seiji Niho

201 papers receiving 5.0k citations

Hit Papers

align trajectories log scale

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations 2018 · 331 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Journal of Clinical Oncology
2017 The Lancet Oncology

Peers

Countries citing papers authored by Seiji Niho

Since Specialization

Citations

This map shows the geographic impact of Seiji Niho's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiji Niho with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiji Niho more than expected).

Fields of papers citing papers by Seiji Niho

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiji Niho. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiji Niho. The network helps show where Seiji Niho may publish in the future.

Co-authors

The 25 scholars most cited alongside Seiji Niho, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Seiji Niho Line = papers co-authored together Seiji Niho links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 213 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial The Lancet Oncology ·Yi‐Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Sashi Nadanaciva, Rickard Sandin, Tony Mok Hit paper breakdown →	2017	854
2	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations Journal of Clinical Oncology ·Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Min Lee, R. Linke, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Eric Sbar, Tao Wang, Jane Liang White, Yi‐Long Wu Hit paper breakdown →	2018	331
3	Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung Clinical Cancer Research ·Tomohiro Miyoshi, Shigeki Umemura, Yuki Matsumura, Sachiyo Mimaki, Satoshi Tada, Hideki Makinoshima, Genichiro Ishii, Hibiki Udagawa, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Hironobu Ohmatsu, Keiju Aokage, Tomoyuki Hishida, Junji Yoshida, Kanji Nagai, Kōichi Goto, Masahiro Tsuboi, Katsuya Tsuchihara	2016	139
4	Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial The Lancet Oncology ·Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Seiji Niho, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Yukari Nagasaka, Mamiko Kawasaki, Tomoaki Yamada, Ryunosuke Machida, Aya Kuchiba, Yuichiro Ohe, Noboru Yamamoto	2020	135
5	First-Line Single Agent Treatment With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study Journal of Clinical Oncology ·Seiji Niho, Kaoru Kubota, Kōichi Goto, Kiyotaka Yoh, Hironobu Ohmatsu, Ryutaro Kakinuma, Nagahiro Saijo, Yutaka Nishiwaki	2005	118
6	Combination Chemotherapy with Irinotecan and Cisplatin for Large-Cell Neuroendocrine Carcinoma of the Lung: A Multicenter Phase II Study Journal of Thoracic Oncology ·Seiji Niho, Hirotsugu Kenmotsu, Ikuo Sekine, Genichiro Ishii, Yuichi Ishikawa, Masayuki Noguchi, Fumihiro Oshita, Shun‐ichi Watanabe, Ryu Nakajima, Hirohito Tada, Kanji Nagai	2013	116
7	Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients Lung Cancer ·Kazuya Takamochi, Junji Yoshida, Koji Murakami, Seiji Niho, Genichiro Ishii, Mitsuyo Nishimura, Yutaka Nishiwaki, Kazuya Suzuki, Kanji Nagai	2004	107
8	Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation Clinical Cancer Research ·Tatsuya Yoshida, Genichiro Ishii, Kōichi Goto, Shinya Neri, Hiroko Hashimoto, Kiyotaka Yoh, Seiji Niho, Shigeki Umemura, Shingo Matsumoto, Hironobu Ohmatsu, Shinsuke Iida, Akio Niimi, Kanji Nagai, Yuichiro Ohe, Atsushi Ochiai	2014	102
9	Mutational status of EGFR and KIT in thymoma and thymic carcinoma Lung Cancer ·Kiyotaka Yoh, Yutaka Nishiwaki, Genichiro Ishii, Kōichi Goto, Kaoru Kubota, Hironobu Ohmatsu, Seiji Niho, Kanji Nagai, Nagahiro Saijo	2008	90
10	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations Drugs ·Tony Mok, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Alka Chawla, Rafael Rosell, J. Corral, Maria Rita Migliorino, Adam Płużański, Kay Noonan, Yiyun Tang, M. Pastel, Keith D. Wilner, Yi‐Long Wu	2020	84
11	A secondary RET mutation in the activation loop conferring resistance to vandetanib Nature Communications ·Takashi Nakaoku, Takashi Kohno, Mitsugu Araki, Seiji Niho, Rakhee Chauhan, Phillip P. Knowles, Katsuya Tsuchihara, Shingo Matsumoto, Yoko Shimada, Sachiyo Mimaki, Genichiro Ishii, Hitoshi Ichikawa, Satoru Nagatoishi, Kouhei Tsumoto, Yasushi Okuno, Kiyotaka Yoh, Neil Q. McDonald, Kōichi Goto	2018	83
12	Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report Thoracic Cancer ·Tomoyuki Naito, Shigeki Umemura, Hiroshi Nakamura, Yoshitaka Zenke, Hibiki Udagawa, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Noriko Motoi, Keijyu Aokage, Masahiro Tsuboi, Genichiro Ishii, Kōichi Goto	2019	74
13	A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients Annals of Oncology ·Yuichiro Ohe, Seiji Niho, Ryutaro Kakinuma, Kaoru Kubota, Hironobu Ohmatsu, Kōichi Goto, Hiroshi Nokihara, Hideo Kunitoh, Nagahiro Saijo, Hiromi Aono, Kenji Watanabe, Mikihiko TANGO, Akira Yokoyama, Yutaka Nishiwaki	2003	73
14	Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden Lung Cancer ·Tomoyuki Naito, Hibiki Udagawa, Shigeki Umemura, Tetsuya Sakai, Yoshitaka Zenke, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Masahiro Tsuboi, Genichiro Ishii, Kōichi Goto	2019	73
15	Monoclonality of both pale cells and cuboidal cells of sclerosing hemangioma of the lung. PubMed ·Seiji Niho, Kenji Suzuki, Tomoyuki Yokose, Tetsuro Kodama, Yutaka Nishiwaki, Hiroyasu Esumi	1998	71
16	Monoclonality of Atypical Adenomatous Hyperplasia of the Lung American Journal Of Pathology ·Seiji Niho, Tomoyuki Yokose, Kenji Suzuki, Tetsuro Kodama, Yutaka Nishiwaki, Kiyoshi Mukai	1999	68
17	Comparison of Pharmacokinetics and Pharmacodynamics of Docetaxel and Cisplatin in Elderly and Non-Elderly Patients: Why Is Toxicity Increased in Elderly Patients? Journal of Clinical Oncology ·Hironobu Minami, Yuichi Ohe, Seiji Niho, Kōichi Goto, Hironobu Ohmatsu, Kaoru Kubota, Ryutaro Kakinuma, Yutaka Nishiwaki, Hiroshi Nokihara, Ikuo Sekine, Nagahiro Saijo, K. Hanada, Hiroyasu Ogata	2004	67
18	Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma Cancer ·Kiyotaka Yoh, Kōichi Goto, Genichiro Ishii, Seiji Niho, Hironobu Ohmatsu, Kaoru Kubota, Ryutaro Kakinuma, Kanji Nagai, Moritaka Suga, Yutaka Nishiwaki	2003	65
19	Protective Effect of Magnesium Preloading on Cisplatin-induced Nephrotoxicity: A Retrospective Study Japanese Journal of Clinical Oncology ·Teruhiko Yoshida, Seiji Niho, M. Toda, Keiko Goto, Kiyotaka Yoh, Shigeki Umemura, Shunya Matsumoto, Hironobu Ohmatsu, Y. Ohe	2014	62
20	Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen Lung Cancer ·Seiji Niho, Y Nishiwaki, Koichi Goto, Hironobu Ohmatsu, T Matsumoto, Fumihiko Hojo, Y. Ohe, Ryutaro Kakinuma, Tetsuro Kodama	2000	60

About Seiji Niho

Seiji Niho is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Epidemiology, Molecular Biology and Surgery, having authored 213 papers that have together received 5.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (116 papers), Lung Cancer Research Studies (87 papers), Lung Cancer Diagnosis and Treatment (62 papers), Neuroendocrine Tumor Research Advances (36 papers), Colorectal Cancer Treatments and Studies (31 papers), Cancer therapeutics and mechanisms (21 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (17 papers) and Cancer Immunotherapy and Biomarkers (15 papers). The work is most often cited by research in Oncology (3.2k citations), Pulmonary and Respiratory Medicine (3.0k citations), Cancer Research (547 citations), Neurology (436 citations) and Epidemiology (894 citations). Seiji Niho has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Kōichi Goto, Kiyotaka Yoh, Hironobu Ohmatsu, Yutaka Nishiwaki, Shingo Matsumoto, Kaoru Kubota, Shigeki Umemura, Yuichiro Ohe, Kazuhiko Nakagawa and Genichiro Ishii. Their work appears in journals such as Journal of Clinical Oncology, Lung Cancer, Annals of Oncology, Journal of Thoracic Oncology and Japanese Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact